2024/03/19 更新

写真a

ツボタ ショウマ
坪田 庄真
TSUBOTA Shoma
所属
大学院医学系研究科 総合医学専攻 生物化学 助教
大学院担当
大学院医学系研究科
学部担当
医学部 医学科
職名
助教
外部リンク

学位 2

  1. 博士(医学) ( 2017年10月   名古屋大学 ) 

  2. 修士(医科学) ( 2013年3月   名古屋大学 ) 

研究キーワード 4

  1. 神経芽腫

  2. 腫瘍生物学

  3. 分子生物学

  4. 神経芽腫

研究分野 1

  1. ライフサイエンス / 腫瘍生物学

経歴 4

  1. 名古屋大学   大学院医学系研究科分子生物学   助教

    2019年4月 - 現在

  2. 名古屋大学大学院医学系研究科分子生物学   助教

    2019年4月 - 現在

      詳細を見る

  3. 名古屋大学大学院医学系研究科分子生物学   研究員

    2017年4月 - 2019年3月

      詳細を見る

  4. 日本学術振興会   特別研究員(DC1)

    2014年4月 - 2017年3月

      詳細を見る

学歴 1

  1. 名古屋大学   大学院医学系研究科   総合医学専攻

    2013年4月 - 2017年3月

      詳細を見る

    備考: 満期退学

    researchmap

 

論文 15

  1. Combination of tumor necrosis factor-alpha and epidermal growth factor induces the adrenergic-to-mesenchymal transdifferentiation in SH-SY5Y neuroblastoma cells 査読有り 国際誌

    Huang Yue, Tsubota Shoma, Nishio Nobuhiro, Takahashi Yoshiyuki, Kadomatsu Kenji

    CANCER SCIENCE   112 巻 ( 2 ) 頁: 715 - 724   2021年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Cancer Science  

    Neuroblastoma, a type of cancer that is common in children, is composed of two genetically clonal but epigenetically distinct cell types: mesenchymal (MES) and adrenergic (ADRN) types, controlled by super-enhancer-associated lineage-specific transcription factor networks. Mesenchymal-type cells are more migratory, resistant to chemotherapy, and prevalent in relapse tumors. Importantly, both cell types spontaneously transdifferentiate into one another, and this interconversion can be induced by genetic manipulations. However, the mechanisms of their spontaneous transdifferentiation and extracellular factors inducing this phenomenon have not yet been elucidated. Using a unique approach involving gene set enrichment analysis, we selected six ADRN and 10 MES candidate factors, possibly inducing ADRN and MES phenotypes, respectively. Treatment with a combination of 10 MES factors clearly induced the MES gene expression profile in ADRN-type SH-SY5Y neuroblastoma cells. Considering the effects on gene expression profile, migration ability, and chemoresistance, a combination of tumor necrosis factor alpha (TNF-α) and epidermal growth factor (EGF) was sufficient to synergistically induce the ADRN-to-MES transdifferentiation in SH-SY5Y cells. In addition, human neuroblastoma cohort analysis revealed that the expression of TNF and EGF receptors was strongly associated with MES gene expression signatures, supporting their important roles in transdifferentiation in vivo. Collectively, we propose a mechanism of neuroblastoma transdifferentiation induced by extracellular growth factors, which can be controlled in clinical situations, providing a new therapeutic possibility.

    DOI: 10.1111/cas.14760

    Web of Science

    Scopus

    PubMed

    researchmap

  2. Origin and initiation mechanisms of neuroblastoma 査読有り 国際誌

    Tsubota Shoma, Kadomatsu Kenji

    CELL AND TISSUE RESEARCH   372 巻 ( 2 ) 頁: 211 - 221   2018年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Cell and Tissue Research  

    Neuroblastoma is an embryonal malignancy that affects normal development of the adrenal medulla and paravertebral sympathetic ganglia in early childhood. Extensive studies have revealed the molecular characteristics of human neuroblastomas, including abnormalities at genome, epigenome and transcriptome levels. However, neuroblastoma initiation mechanisms and even its origin are long-standing mysteries. In this review article, we summarize the current knowledge about normal development of putative neuroblastoma sources, namely sympathoadrenal lineage of neural crest cells and Schwann cell precursors that were recently identified as the source of adrenal chromaffin cells. A plausible origin of enigmatic stage 4S neuroblastoma is also discussed. With regard to the initiation mechanisms, we review genetic abnormalities in neuroblastomas and their possible association to initiation mechanisms. We also summarize evidences of neuroblastoma initiation observed in genetically engineered animal models, in which epigenetic alterations were involved, including transcriptomic upregulation by N-Myc and downregulation by polycomb repressive complex 2. Finally, several in vitro experimental methods are proposed that hopefully will accelerate our comprehension of neuroblastoma initiation. Thus, this review summarizes the state-of-the-art knowledge about the mechanisms of neuroblastoma initiation, which is critical for developing new strategies to cure children with neuroblastoma.

    DOI: 10.1007/s00441-018-2796-z

    Web of Science

    Scopus

    PubMed

    researchmap

  3. PRC2-Mediated Transcriptomic Alterations at the Embryonic Stage Govern Tumorigenesis and Clinical Outcome in MYCN-Driven Neuroblastoma 査読有り 国際誌

    Tsubota Shoma, Kishida Satoshi, Shimamura Teppei, Ohira Miki, Yamashita Satoshi, Cao Dongliang, Kiyonari Shinichi, Ushijima Toshikazu, Kadomatsu Kenji

    CANCER RESEARCH   77 巻 ( 19 ) 頁: 5259 - 5271   2017年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Cancer Research  

    Pediatric cancers such as neuroblastoma are thought to involve a dysregulation of embryonic development. However, it has been difficult to identify the critical events that trigger tumorigenesis and differentiate them from normal development. In this study, we report the establishment of a spheroid culture method that enriches early-stage tumor cells from TH-MYCN mice, a preclinical model of neuroblastoma. Using this method, we found that tumorigenic cells were evident as early as day E13.5 during embryo development, when the MYC and PRC2 transcriptomes were significantly altered. Ezh2, an essential component of PRC2, was expressed in embryonic and postnatal tumor lesions and physically associated with N-MYC and we observed that H3K27me3 was increased at PRC2 target genes. PRC2 inhibition suppressed in vitro sphere formation, derepressed its target genes, and suppressed in situ tumor growth. In clinical specimens, expression of MYC and PRC2 target genes correlated strongly and predicted survival outcomes. Together, our findings highlighted PRC2-mediated transcriptional control during embryogenesis as a critical step in the development and clinical outcome of neuroblastoma.

    DOI: 10.1158/0008-5472.CAN-16-3144

    Web of Science

    Scopus

    PubMed

    researchmap

  4. Detecting and exploring kidney-derived extracellular vesicles in plasma.

    Komatsu S, Kato N, Kitai H, Funahashi Y, Noda Y, Tsubota S, Tanaka A, Sato Y, Maeda K, Saito S, Furuhashi K, Ishimoto T, Kosugi T, Maruyama S, Kadomatsu K

    Clinical and experimental nephrology     2024年3月

     詳細を見る

    記述言語:英語   出版者・発行元:Clinical and Experimental Nephrology  

    Background: Extracellular vesicles (EVs) have received considerable attention as ideal biomarkers for kidney diseases. Most reports have focused on urinary EVs, that are mainly derived from the cells in the urinary tract. However, the detection and the application of kidney-derived EVs in plasma remains uncertain. Methods: We examined the kidney-derived small EVs (sEVs) in plasma that were supposedly released from renal mesangial and glomerular endothelial cells, using clinical samples from healthy controls and patients with kidney transplants. Plasma from healthy controls underwent ultracentrifugation, followed by on-bead flow cytometry, targeting α8 integrin, an antigen-specific to mesangial cells. To confirm the presence of kidney-derived sEVs in peripheral blood, plasma from ABO-incompatible kidney transplant recipients was ultracentrifuged, followed by western blotting for donor blood type antigens. Results: Immunohistochemistry and immunoelectron microscopy confirmed α8 integrin expression in kidney mesangial cells and their sEVs. The CD9-α8 integrin double-positive sEVs were successfully detected using on-bead flow cytometry. Western blot analysis further revealed transplanted kidney-derived sEVs containing blood type B antigens in non-blood type B recipients, who had received kidneys from blood type B donors. Notably, a patient experiencing graft kidney loss exhibited diminished signals of sEVs containing donor blood type antigens. Conclusion: Our findings demonstrate the potential usefulness of kidney-derived sEVs in plasma in future research for kidney diseases.

    DOI: 10.1007/s10157-024-02464-z

    Scopus

    PubMed

  5. Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma

    Zhai, L; Balachandran, A; Larkin, R; Seneviratne, JA; Chung, SA; Lalwani, A; Tsubota, S; Beck, D; Kadomatsu, K; Beckers, A; Durink, K; De Preter, K; Speleman, F; Haber, M; Norris, MD; Swarbrick, A; Cheung, BB; Marshall, GM; Carter, DR

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES   24 巻 ( 21 )   2023年11月

     詳細を見る

    記述言語:英語   出版者・発行元:International Journal of Molecular Sciences  

    MYCN amplification occurs in approximately 20–30% of neuroblastoma patients and correlates with poor prognosis. The TH-MYCN transgenic mouse model mimics the development of human high-risk neuroblastoma and provides strong evidence for the oncogenic function of MYCN. In this study, we identified mitotic dysregulation as a hallmark of tumor initiation in the pre-cancerous ganglia from TH-MYCN mice that persists through tumor progression. Single-cell quantitative-PCR of coeliac ganglia from 10-day-old TH-MYCN mice revealed overexpression of mitotic genes in a subpopulation of premalignant neuroblasts at a level similar to single cells derived from established tumors. Prophylactic treatment using antimitotic agents barasertib and vincristine significantly delayed the onset of tumor formation, reduced pre-malignant neuroblast hyperplasia, and prolonged survival in TH-MYCN mice. Analysis of human neuroblastoma tumor cohorts showed a strong correlation between dysregulated mitosis and features of MYCN amplification, such as MYC(N) transcriptional activity, poor overall survival, and other clinical predictors of aggressive disease. To explore the therapeutic potential of targeting mitotic dysregulation, we showed that genetic and chemical inhibition of mitosis led to selective cell death in neuroblastoma cell lines with MYCN over-expression. Moreover, combination therapy with antimitotic compounds and BCL2 inhibitors exploited mitotic stress induced by antimitotics and was synergistically toxic to neuroblastoma cell lines. These results collectively suggest that mitotic dysregulation is a key component of tumorigenesis in early neuroblasts, which can be inhibited by the combination of antimitotic compounds and pro-apoptotic compounds in MYCN-driven neuroblastoma.

    DOI: 10.3390/ijms242115571

    Web of Science

    Scopus

    PubMed

  6. Systematic characterization of seed overlap microRNA cotargeting associated with lupus pathogenesis 国際誌

    Kitai Hiroki, Kato Noritoshi, Ogami Koichi, Komatsu Shintaro, Watanabe Yu, Yoshino Seiko, Koshi Eri, Tsubota Shoma, Funahashi Yoshio, Maeda Takahiro, Furuhashi Kazuhiro, Ishimoto Takuji, Kosugi Tomoki, Maruyama Shoichi, Kadomatsu Kenji, Suzuki Hiroshi I

    BMC BIOLOGY   20 巻 ( 1 ) 頁: 248 - 248   2022年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BMC Biology  

    Background: Combinatorial gene regulation by multiple microRNAs (miRNAs) is widespread and closely spaced target sites often act cooperatively to achieve stronger repression (“neighborhood” miRNA cotargeting). While miRNA cotarget sites are suggested to be more conserved and implicated in developmental control, the pathological significance of miRNA cotargeting remains elusive. Results: Here, we report the pathogenic impacts of combinatorial miRNA regulation on inflammation in systemic lupus erythematosus (SLE). In the SLE mouse model, we identified the downregulation of two miRNAs, miR-128 and miR-148a, by TLR7 stimulation in plasmacytoid dendritic cells. Functional analyses using human cell lines demonstrated that miR-128 and miR-148a additively target KLF4 via extensively overlapping target sites (“seed overlap” miRNA cotargeting) and suppress the inflammatory responses. At the transcriptome level, “seed overlap” miRNA cotargeting increases susceptibility to downregulation by two miRNAs, consistent with additive but not cooperative recruitment of two miRNAs. Systematic characterization further revealed that extensive “seed overlap” is a prevalent feature among broadly conserved miRNAs. Highly conserved target sites of broadly conserved miRNAs are largely divided into two classes—those conserved among eutherian mammals and from human to Coelacanth, and the latter, including KLF4-cotargeting sites, has a stronger association with both “seed overlap” and “neighborhood” miRNA cotargeting. Furthermore, a deeply conserved miRNA target class has a higher probability of haplo-insufficient genes. Conclusions: Our study collectively suggests the complexity of distinct modes of miRNA cotargeting and the importance of their perturbations in human diseases.

    DOI: 10.1186/s12915-022-01447-4

    Web of Science

    Scopus

    PubMed

    researchmap

  7. Basigin deficiency prevents anaplerosis and ameliorates insulin resistance and hepatosteatosis

    Ryuge Akihiro, Kosugi Tomoki, Maeda Kayaho, Banno Ryoichi, Gou Yang, Zaitsu Kei, Ito Takanori, Sato Yuka, Hirayama Akiyoshi, Tsubota Shoma, Honda Takashi, Nakajima Kazuki, Ozaki Tomoya, Kondoh Kunio, Takahashi Kazuo, Kato Noritoshi, Ishimoto Takuji, Soga Tomoyoshi, Nakagawa Takahiko, Koike Teruhiko, Arima Hiroshi, Yuzawa Yukio, Minokoshi Yasuhiko, Maruyama Shoichi, Kadomatsu Kenji

    JCI INSIGHT   6 巻 ( 20 )   2021年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:JCI Insight  

    Monocarboxylates, such as lactate and pyruvate, are precursors for biosynthetic pathways, including those for glucose, lipids, and amino acids via the tricarboxylic acid (TCA) cycle and adjacent metabolic networks. The transportation of monocarboxylates across the cellular membrane is performed primarily by monocarboxylate transporters (MCTs), the membrane localization and stabilization of which are facilitated by the transmembrane protein basigin (BSG). Here, we demonstrate that the MCT/BSG axis sits at a crucial intersection of cellular metabolism. Abolishment of MCT1 in the plasma membrane was achieved by Bsg depletion, which led to gluconeogenesis impairment via preventing the influx of lactate and pyruvate into the cell, consequently suppressing the TCA cycle. This net anaplerosis suppression was compensated in part by the increased utilization of glycogenic amino acids (e.g., alanine and glutamine) into the TCA cycle and by activated ketogenesis through fatty acid β-oxidation. Complementary to these observations, hyperglycemia and hepatic steatosis induced by a high-fat diet were ameliorated in Bsg-deficient mice. Furthermore, Bsg deficiency significantly improved insulin resistance induced by a high-fat diet. Taken together, the plasma membrane–selective modulation of lactate and pyruvate transport through BSG inhibition could potentiate metabolic flexibility to treat metabolic diseases.

    DOI: 10.1172/jci.insight.142464

    Web of Science

    Scopus

    PubMed

    researchmap

  8. Screening of novel Midkine binding protein by BioID2-based proximity labeling 査読有り

    Komata Yosuke, Tsubota Shoma, Sakamoto Kazuma, Ikematsu Shinya, Kadomatsu Kenji

    NAGOYA JOURNAL OF MEDICAL SCIENCE   83 巻 ( 3 ) 頁: 495 - 508   2021年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Nagoya Journal of Medical Science  

    Midkine (MK), a heparin-binding growth factor, is associated with the poor prognosis of the pediatric tumor, neuroblastoma. MK would be a druggable target as many studies showed inhibition of its function in various cancers suppressed tumor developments. To establish the therapy targeting MK, identification of its binding partners, and elucidation of its intracellular signaling are needed. It was reported that exogenous MK induced phosphorylation of ribosomal protein S6 (RPS6) downstream of mTOR signaling. Using RPS6 phosphorylation as a marker of MK response, we searched for MK reactive cell lines. We found that MK cell lines expressing less MK tended to respond better to MK. Next, using an MK reactive neuroblastoma cell line, MK-knocked down SH-SY5Y cells, we employed a proximity-dependent biotin identification method, which was invented to evaluate protein-protein interactions by biotinylation. We confirmed that secreted MK fused to the biotin ligase BioID2 (MK-BioID2) was able to biotinylate proteins from the cells. Biotinylated proteins were identified by liquid chromatography-mass spectrometry analyses. Twenty five proteins were found to be overlapped after three independent experiments, among which insulin-like growth binding protein 2 (IGFBP2) was further analyzed. IGFBP2 was indeed detected with immunoblotting after streptavidin pull down of MK-BioID2 labeled cell extract of MK-knocked down SH-SY5Y cells. Our study suggests that the BioID2 method is useful to identify binding partners of growth factors.

    DOI: 10.18999/nagjms.83.3.495

    Web of Science

    Scopus

    PubMed

    researchmap

  9. Thymidylate synthase inhibitor raltitrexed can induce high levels of DNA damage inMYCN-amplified neuroblastoma cells 査読有り 国際誌

    Yamashita Ken, Kiyonari Shinichi, Tsubota Shoma, Kishida Satoshi, Sakai Ryuichi, Kadomatsu Kenji

    CANCER SCIENCE   111 巻 ( 7 ) 頁: 2431 - 2439   2020年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Cancer Science  

    MYCN gene amplification is consistently associated with poor prognosis in patients with neuroblastoma, a pediatric tumor arising from the sympathetic nervous system. Conventional anticancer drugs, such as alkylating agents and platinum compounds, have been used for the treatment of high-risk patients with MYCN-amplified neuroblastoma, whereas molecule-targeting drugs have not yet been approved. Therefore, the development of a safe and effective therapeutic approach is highly desired. Although thymidylate synthase inhibitors are widely used for colorectal and gastric cancers, their usefulness in neuroblastoma has not been well studied. Here, we investigated the efficacies of approved antifolates, methotrexate, pemetrexed, and raltitrexed (RTX), on MYCN-amplified and nonamplified neuroblastoma cell lines. Cell growth-inhibitory assay revealed that RTX showed a superior inhibitory activity against MYCN-amplified cell lines. We found no significant differences in the protein expression levels of the antifolate transporter or thymidylate synthase, a primary target of RTX, among the cell lines. Because thymidine supplementation could rescue the RTX-induced cell growth suppression, the effect of RTX was mainly due to the reduction in dTTP synthesis. Interestingly, RTX treatments induced single-stranded DNA damage response in MYCN-amplified cells to a greater extent than in the nonamplified cells. We propose that the high DNA replication stress and elevated levels of DNA damage, which are a result of deregulated expression of MYCN target genes, could be the cause of increased sensitivity to RTX.

    DOI: 10.1111/cas.14485

    Web of Science

    Scopus

    PubMed

    researchmap

  10. 新規tagmentation-assisted PCR法を用いたCD19キメラ抗原受容体遺伝子導入T細胞の遺伝子挿入部位解析(Integration mapping of CD19 chimeric antigen receptor T cells by novel tagmentation-assisted PCR) 査読有り 国際誌

    濱田 太立, 奥野 友介, 西尾 信博, 鈴木 哲, 川島 希, 村松 秀城, 坪田 庄真, Wilson Matthew H., 盛田 大介, 片岡 伸介, 市川 大輔, 村上 典寛, 谷口 理恵子, 鈴木 喬悟, 小島 大英, 関屋 由子, 西川 英里, 成田 敦, 濱 麻人, 小島 勢二, 中沢 洋三, 高橋 義行

    臨床血液   59 巻 ( 9 ) 頁: 1586 - 1586   2018年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:(一社)日本血液学会-東京事務局  

    researchmap

  11. Integration Mapping of piggyBac-Mediated CD19 Chimeric Antigen Receptor T Cells Analyzed by Novel Tagmentation-Assisted PCR 査読有り 国際誌

    Hamada Motoharu, Nishio Nobuhiro, Okuno Yusuke, Suzuki Satoshi, Kawashima Nozomu, Muramatsu Hideki, Tsubota Shoma, Wilson Matthew H., Morita Daisuke, Kataoka Shinsuke, Ichikawa Daisuke, Murakami Norihiro, Taniguchi Rieko, Suzuki Kyogo, Kojima Daiei, Sekiya Yuko, Nishikawa Eri, Narita Atsushi, Hama Asahito, Kojima Seiji, Nakazawa Yozo, Takahashi Yoshiyuki

    EBIOMEDICINE   34 巻   頁: 18 - 26   2018年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:EBioMedicine  

    Insertional mutagenesis is an important risk with all genetically modified cell therapies, including chimeric antigen receptor (CAR)-T cell therapy used for hematological malignancies. Here we describe a new tagmentation-assisted PCR (tag-PCR) system that can determine the integration sites of transgenes without using restriction enzyme digestion (which can potentially bias the detection) and allows library preparation in fewer steps than with other methods. Using this system, we compared the integration sites of CD19-specific CAR genes in final T cell products generated by retrovirus-based and lentivirus-based gene transfer and by the piggyBac transposon system. The piggyBac system demonstrated lower preference than the retroviral system for integration near transcriptional start sites and CpG islands and higher preference than the lentiviral system for integration into genomic safe harbors. Integration into or near proto-oncogenes was similar in all three systems. Tag-PCR mapping is a useful technique for assessing the risk of insertional mutagenesis.

    DOI: 10.1016/j.ebiom.2018.07.008

    Web of Science

    Scopus

    PubMed

    researchmap

  12. Development of the sympathoadrenal lineage from neural crest and neuroblastoma 査読有り 国際誌

    Tsubota Shoma, Kadomatsu Kenji

    CANCER SCIENCE   109 巻   頁: 22 - 22   2018年1月

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    Web of Science

  13. Neurocan, an extracellular chondroitin sulfate proteoglycan, stimulates neuroblastoma cells to promote malignant phenotypes 査読有り 国際誌

    Su Zhendong, Kishida Satoshi, Tsubota Shoma, Sakamoto Kazuma, Cao Dongliang, Kiyonari Shinichi, Ohira Miki, Kamijo Takehiko, Narita Atsushi, Xu Yinyan, Takahashi Yoshiyuki, Kadomatsu Kenji

    ONCOTARGET   8 巻 ( 63 ) 頁: 106296 - 106310   2017年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Oncotarget  

    Neurocan (NCAN), a secreted chondroitin sulfate proteoglycan, is one of the major inhibitory molecules for axon regeneration in nervous injury. However, its role in cancer is not clear. Here we observed that high NCAN expression was closely associated with the unfavorable outcome of neuroblastoma (NB). NCAN was also highly and ubiquitously expressed in the early lesions and terminal tumor of TH-MYCN mice, a NB model. Interestingly, exogenous NCAN (i.e., overexpression, recombinant protein and conditioned medium) transformed adherent NB cells into spheres whose malignancies in vitro (anchorage-independent growth and chemoresistance) and in vivo (xenograft tumor growth) were potentiated. Both chondroitin sulfate sugar chains and NCAN's core protein were essential for the sphere formation. The CSG3 domain was essential in the moiety of NCAN. Our comprehensive microarray analysis and RT-qPCR of mRNA expression suggested that NCAN treatment promoted cell division, and urged cells to undifferentiated state. The knockdown of NCAN in tumor sphere cells cultured from TH-MYCN mice resulted in growth suppression in vitro and in vivo. Our findings suggest that NCAN, which stimulates NB cells to promote malignant phenotypes, is an extracellular molecule providing a growth advantage to cancer cells.

    DOI: 10.18632/oncotarget.22435

    Web of Science

    Scopus

    PubMed

    researchmap

  14. Neuroblastoma stem cells and CFC1 査読有り 国際誌

    Tsubota Shoma, Kadomatsu Kenji

    ONCOTARGET   8 巻 ( 28 ) 頁: 45032 - 45033   2017年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Oncotarget  

    DOI: 10.18632/oncotarget.18464

    Web of Science

    Scopus

    PubMed

    researchmap

  15. Origin and mechanism of neuroblastoma. 査読有り 国際誌

    Tsubota S, Kadomatsu K

    Oncoscience   4 巻 ( 7-8 ) 頁: 70 - 72   2017年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Oncoscience  

    Neuroblastoma is the most common extracranial solid tumor in childhood, and develops mainly in the adrenal medulla but also in the sympathetic ganglia. Some cases of neuroblastoma show spontaneous regression. Particularly, stage 4S, where S stands for “special”, exhibits spontaneous regression despite multifocal tumors. Another interesting feature is that, with few exceptions, driver gene mutations are rare in neuroblastoma, while copy number alterations are common, including MYCN amplification, 17q gain, and others, suggesting the involvement of epigenetic regulation [1]. These features suggest that neuroblastoma tumorigenesis is closely related to the development of the sympathoadrenal lineage. However, the underlying mechanisms, even the origin of neuroblastoma, remain largely obscure. To elucidate those mechanisms, three important papers have been recently published [2-4].

    DOI: 10.18632/oncoscience.360

    Scopus

    PubMed

    researchmap

▼全件表示

科研費 4

  1. 神経芽腫の時期・細胞特異的な発生機構解明

    研究課題/研究課題番号:22K07186  2022年4月 - 2025年3月

    科学研究費助成事業  基盤研究(C)

    坪田 庄真

      詳細を見る

    担当区分:研究代表者 

    配分額:4290000円 ( 直接経費:3300000円 、 間接経費:990000円 )

    小児がんの一つである神経芽腫は、様々なゲノム異常とエピゲノム異常が混在し、治療抵抗性から自然退縮まで表現型が極めて多様である。しかし、そもそもなぜ神経芽腫が発生するのか、特にがん化の時期や細胞特異性、神経芽腫を成り立たせる因子(発生に必須の遺伝子)については不明である。本研究では、独自の培養技術とシングルセル遺伝子発現解析の結果を活用し、マウス副腎組織を対象とした各種細胞タイプの選別、in vitroでのがん化誘導による神経芽腫の起源となる細胞(がん化する細胞タイプ)の同定、網羅的な遺伝子発現解析や介入実験を行い、神経芽腫の時期や細胞特異性に着目した発生機構の解明を目的とする。

  2. MYCNとEZH2が引き起こすエピゲノム異常による神経芽腫発生機構の解明

    研究課題/研究課題番号:20K16355  2020年4月 - 2022年3月

    日本学術振興会  科学研究費助成事業  若手研究

    坪田 庄真

      詳細を見る

    担当区分:研究代表者 

    配分額:4290000円 ( 直接経費:3300000円 、 間接経費:990000円 )

    本研究では、神経芽腫のがん遺伝子として知られるMYCNによる発がんにおいて、MYCNとエピゲノム制御複合体PRC2の責任分子であるEZH2が物理的に結合する意義・その機構を解明する。具体的に、MYCNとEZH2の結合様式を明らかにし、EZH2と結合しないMYCN変異体を用いて神経芽腫の発生を検証する。また、それぞれのゲノム上での局在やエピゲノム修飾、遺伝子発現を網羅的に解析する。
    小児がん神経芽腫は、がん遺伝子として知られるMYCNにより引き起こされる。これまで研究代表者は、MYCNとエピゲノム制御因子のEZH2によるがん化機構の解明に向け研究を行ってきた。本研究で、MYCNのMB2ドメインがEZH2と結合するという既報を再現できなかった。しかしMB2ドメインは、MYCNの形質転換能に必須である可能性を示唆するデータを得た。また、MYCNとEZH2がゲノム上のMYCNターゲット遺伝子のプロモーター部位に共局在し新たな遺伝子発現制御機構の存在を示唆する結果を得た。
    MYCNの過剰発現は神経芽腫を引き起こす原因の1つであるが、その構造的特性から特異的な阻害剤の開発は困難である。そのため、MYCNによるがん化の詳細な機構を解明することで、MYCNそのものではなくMYCNにより引き起こされる異常を標的とした治療薬の開発が可能となる。本研究はその基盤となるMYCNとEZH2の結合が、MYCNによる神経芽腫の発生に必須であるということを調査するものであり、これが達成されればこの結合阻害が新たな治療標的になりうる。

    researchmap

  3. MYCN-PRC2を基軸にしたエピゲノム異常による神経芽腫発生機構の解明

    研究課題/研究課題番号:18K15208  2018年4月 - 2020年3月

    日本学術振興会  科学研究費助成事業  若手研究

    坪田 庄真

      詳細を見る

    担当区分:研究代表者 

    配分額:4160000円 ( 直接経費:3200000円 、 間接経費:960000円 )

    小児がんの1つである神経芽腫は、がん遺伝子として知られるMYCNにより引き起こされる。これまで研究代表者は、MYCNによる神経芽腫の発生に、EZH2と言うエピゲノム制御因子が重要であり、MYCNと結合すること、EZH2機能を阻害することで神経芽腫の増殖を抑えられることを報告した。本研究課題では、MYCNとEZH2が結合することが神経芽腫の発生に必須であるかどうかを検討したが、そもそもMYCNの一部がEZH2との結合に必要であるという既報を再現できず、研究期間内に目的の達成には至らなかった。
    MYCNの過剰発現は神経芽腫を引き起こす原因の1つであるが、その構造的特性から特異的な阻害剤の開発は困難である。そのため、MYCNによるがん化の詳細な機構を解明することで、MYCNそのものではなくMYCNにより引き起こされる異常を標的とした治療薬の開発が可能となる。本研究はその基盤となるMYCNとEZH2の結合が、MYCNによる神経芽腫の発生に必須であるということを調査するものであり、これが達成されればこの結合阻害が新たな治療標的になりうる。

    researchmap

  4. MYCN-Tgマウスにおける神経芽腫発生の運命決定機構の解明

    研究課題/研究課題番号:14J00157  2014年4月 - 2017年3月

    日本学術振興会  科学研究費助成事業 特別研究員奨励費  特別研究員奨励費

    坪田 庄真

      詳細を見る

    本研究は、小児がんの一つである神経芽腫のMYCN-Tgマウスモデルにおける腫瘍発生の運命決定機構の解明である。特に腫瘍形成初期イベントに着目し、MYCN-Tgマウスの組織とSpheroid cultureによって得られた細胞を対象に網羅的解析を行い、エピゲノム制御分子であるPRC2 が神経芽腫の発生初期において重要な分子の一つであることを明らかにした。PRC2の中でもヒストンメチル基転移酵素のEzh2が、ヒストンH3の27番目のリジンをトリメチル化(H3K27me3)しターゲット分子の発現を抑制する。
    MYCN-Tg由来Sphereでは野生型由来Sphereに比べ、PRC2ターゲット遺伝子の発現が低下していた。ゲノムレベルでのH3K27me3修飾状態を調べるためにChIP-sequencingを行った。その結果、MYCN-Tg由来SphereではPRC2ターゲット分子の遺伝子領域(特にプロモーター)でH3K27me3が増加していた。PRC2ターゲット遺伝子の発現低下が、H3K27me3レベルの増加によるものであることが示唆された。
    Ezh2に対するshRNAとそのヒストンメチル基転移活性を阻害する薬を用い介入実験を行った。その結果、ノックダウン及び薬のどちらもin vitroでの細胞増殖を著しく抑制した。また、阻害剤はin vivoにおいてもTH-MYCNマウスの腫瘍形成を著しく阻害した。神経芽腫においてEzh2がその生存に必須であることを示唆している。
    最後に、約500例のヒト神経芽腫の発現解析データを調べた結果、より悪性度が高い患者でPRC2ターゲットの発現が低く、予後不良と相関していることが明らかになった。
    これまで神経芽腫におけるPRC2の役割、特に腫瘍発生の初期に関わっているという報告はなく、新規な知見を得ることができた。

    researchmap